Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor TypesPRNewsWire • 12/01/22
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 34th Annual Healthcare Conference (Transcript)Seeking Alpha • 11/30/22
Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority ReviewPRNewsWire • 11/30/22
Regeneron Pharmaceuticals, Inc. (REGN) 5th Annual Evercore ISI HealthCONx Conference (Transcript)Seeking Alpha • 11/29/22
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor HistologyPRNewsWire • 11/22/22
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of CancerPRNewsWire • 11/17/22
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference - (Transcript)Seeking Alpha • 11/16/22
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo NodularisPRNewsWire • 11/11/22
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)PRNewsWire • 11/08/22
Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular DegenerationPRNewsWire • 11/04/22